To use gene therapy to replace retGC1 to restore visual function

Not so long ago there was a research about using gene therapy to replace retGC1 to restore visual function. In the research with recombinant proteins, mice lacking the protein retGC1, which is deficient in humans suffering Leber congenital amaurosis-1 (LCA1), a disorder that causes severe visual impairment beginning in infancy, received gene therapy to replace retGC1 and showed fully restored visual function that persisted for at least 6 months. The success would strongly support clinical testing of a gene therapy targeted to the retinas of LCA1 patients as the researchers concluded.

Sanford Boye, Shannon Boye, and coauthors from University of Florida College of Medicine, Gainesville, University of Oklahoma College of Medicine, Oklahoma City, and Salus University, Elkins Park, PA, are the authors of the article. They emphasize the need for a treatment strategy targeting the loss of cone function that occurs in the eyes of patients with LCA1. They describe a gene replacement approach that uses an adeno-associated viral (AAV) vector to deliver the gene encoding the retGC1 protein to the cone-rich central retina in an all-cone mouse model deficient in retGC1. They report their results conclusions in the article.

"This study shows the tremendous potential of recombinant (rAAV) gene therapy for the effective treatment of genetic causes of vision loss," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA.

This article about the Gene therapy is available free on the Human Gene Therapy website before September 30, 2015. Want to know more? Go and see! Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers recombinant proteins like recombinant KEL at good prices.